Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Raw Materials of $74.3 million for Q1 2026, down 2.84% year-over-year from $76.5 million in Q1 2025, and down 10.21% quarter-over-quarter from $82.8 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Raw Materials history runs 11 years deep, the most recent figure standing at $74.3 million for Q1 2026.
- In Q1 2026, Raw Materials fell 2.84% year-over-year to $74.3 million; the TTM figure through Mar 2026 stood at $74.3 million (down 2.84% YoY), while the FY2025 annual figure was $82.8 million, up 18.7% from the prior year.
- Raw Materials for Q1 2026 stood at $74.3 million, down from $82.8 million in the prior quarter.
- The five-year high for Raw Materials was $83.7 million in Q2 2025, with the low at $5.2 million in Q1 2023.
- The 5-year median for Raw Materials is $42.2 million (2024), against an average of $41.6 million.
- The sharpest annual moves came in 2023 and 2024: Raw Materials decreased 16.62% in 2023, then surged 934.36% in 2024.
- Acadia Pharmaceuticals' Raw Materials stood at $5.2 million in 2022, then soared by 501.34% to $31.3 million in 2023, then jumped by 122.73% to $69.7 million in 2024, then increased by 18.7% to $82.8 million in 2025, then retreated by 10.21% to $74.3 million in 2026.
- Business Quant data shows ACAD's Raw Materials at $74.3 million in Q1 2026, $82.8 million in Q4 2025, and $77.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.16 Mn |
| Mar 31, 2026 | 74.33 Mn |
| Dec 31, 2025 | 82.78 Mn |
| Sep 30, 2025 | 77.78 Mn |
| Jun 30, 2025 | 83.68 Mn |
| Mar 31, 2025 | 76.50 Mn |
| Dec 31, 2024 | 69.74 Mn |
| Sep 30, 2024 | 42.18 Mn |
| Jun 30, 2024 | 63.50 Mn |
| Mar 31, 2024 | 53.52 Mn |
| Dec 31, 2023 | 31.31 Mn |
| Sep 30, 2023 | 16.26 Mn |
| Jun 30, 2023 | 6.81 Mn |
| Mar 31, 2023 | 5.17 Mn |
| Dec 31, 2022 | 5.21 Mn |
| Sep 30, 2022 | 5.99 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Mar 31, 2022 | 6.21 Mn |
| Dec 31, 2021 | 6.22 Mn |
| Sep 30, 2021 | 6.22 Mn |